NCT03800108 (FREQUENCY) is a NA clinical trial of Personalized DBS adjustments in Parkinson Disease, sponsored by Darlene Floden.

Who is sponsoring NCT03800108?

NCT03800108 is sponsored by Darlene Floden.

What drugs are being tested in NCT03800108?

Interventions in NCT03800108: Personalized DBS adjustments.

What condition does NCT03800108 study?

NCT03800108 studies Parkinson Disease.

Is NCT03800108 still recruiting?

NCT03800108 is currently terminated. Last updated 5 February 2025.

Are results published for NCT03800108?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-05 · How we verify

NCT03800108: FREQUENCY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stimulation Parameters and Non-motor Symptoms in PD Treated With DBS

Terminated NA Results posted Last updated 5 February 2025

What this trial tests

NA trial testing Personalized DBS adjustments in Parkinson Disease in 5 participants. Terminated before completion.

Timeline

30 May 2018

Primary endpoint
14 January 2020

14 January 2020

Quick facts

Lead sponsor	Darlene Floden
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	5
Start date	30 May 2018
Primary completion	14 January 2020
Estimated completion	14 January 2020
Sites	1 location across United States

Drugs / interventions tested

Personalized DBS adjustments

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Darlene Floden

Who can join

Adults 40 to 70, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Reaction Time Primary · 30-60 minutes after stimulation adjustment

Subjects will complete one or more measures of cognitive processing requiring speeded responses to stimuli. Changes in reaction time will be compared to 'off stimulation'

Group	Value	95% CI
Personalized DBS Adjustments	2
Personalized DBS Adjustments	1

Verbal Fluency Primary · 30-60 minutes after stimulation adjustment

Change in the number words that patients generate to letter or semantic category cues will be compared to 'off stimulation'

Change at Dorsal High Hz

Group	Value	95% CI
Personalized DBS Adjustments	6.3	2 – 11

Change at Ventral Low Hz

Group	Value	95% CI
Personalized DBS Adjustments	-0.3	-5 – 5

Finger Tapping Speed Primary · 30-60 minutes after stimulation adjustment

Change in upper extremity speed (# of taps in 10 seconds) will be compared to 'off stimulation'

Taps change at Dorsal High Hz

Group	Value	95% CI
Personalized DBS Adjustments	2.1	-1 – 5

Taps change at Ventral Low Hz

Group	Value	95% CI
Personalized DBS Adjustments	2.2	.66 – 4.5

Sponsor's own description

This study evaluates the role of subthalamic nucleus (STN) stimulation location and frequency on a range of cognitive processes in Parkinson's patients who have undergone Deep Brain Stimulation (DBS).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03800108 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Darlene Floden
Last refreshed: 5 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03800108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing